EP 4127136 A1 20230208 - USE OF EXOSOME-BASED DELIVERY OF NF-KB INHIBITORS
Title (en)
USE OF EXOSOME-BASED DELIVERY OF NF-KB INHIBITORS
Title (de)
VERWENDUNG VON EXOSOMENBASIERTER FREISETZUNG VON NF-KB-INHIBITOREN
Title (fr)
UTILISATION D'ADMINISTRATION D'INHIBITEURS DE NF-KB À PARTIR D'EXOSOMES
Publication
Application
Priority
- IB 2021052708 W 20210331
- KR 20200039011 A 20200331
- US 202063112154 P 20201110
- US 202063112155 P 20201111
Abstract (en)
[origin: WO2021198961A1] The present disclosure relates to methods for treating acute kidney injury using exosome containing NF-κB inhibitors. The present disclosure relates to methods for treating diseases induced by sepsis using exosome containing NF-κB inhibitor.
IPC 8 full level
C12N 5/071 (2006.01); A61K 35/12 (2006.01); C07K 14/47 (2006.01); C12N 5/073 (2006.01)
CPC (source: EP KR)
A61K 9/5063 (2013.01 - KR); A61K 35/12 (2013.01 - EP); A61K 38/1709 (2013.01 - EP KR); A61P 13/12 (2018.01 - KR); C07K 14/4703 (2013.01 - EP KR); C12N 5/0603 (2013.01 - KR); C12N 5/0686 (2013.01 - KR); A61P 13/12 (2018.01 - EP); A61P 29/00 (2018.01 - EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2021198961 A1 20211007; AU 2021247253 A1 20221020; AU 2021247253 B2 20241031; CA 3173845 A1 20211007; CN 115335079 A 20221111; EP 4127136 A1 20230208; EP 4127136 A4 20240403; JP 2023519700 A 20230512; JP 7498293 B2 20240611; KR 20210124180 A 20211014; KR 20220149781 A 20221108
DOCDB simple family (application)
IB 2021052708 W 20210331; AU 2021247253 A 20210331; CA 3173845 A 20210331; CN 202180024099 A 20210331; EP 21781109 A 20210331; JP 2022559527 A 20210331; KR 20217014385 A 20210331; KR 20227034736 A 20210331